<DOC>
	<DOCNO>NCT00224107</DOCNO>
	<brief_summary>A new drug benign prostatic hyperplasia compare placebo determine safe effective . The study last approximately 20 week .</brief_summary>
	<brief_title>A New Drug Benign Prostatic Hyperplasia ( BPH ) Compared With Placebo</brief_title>
	<detailed_description>This multi-center , double-blind , placebo control , parallel , 12 week treatment trial men sign symptom benign prostatic hyperplasia . The following procedure utilized : physical exam , electrocardiogram , clinical laboratory test , vital sign , International Prostate Symptom Score , maximum urine flow rate , pharmacokinetics , adverse event , concomitant medication , quality life , compliance .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Males good general health least 50 year age , symptom moderate severe benign prostatic hyperplasia . Medical condition would confound efficacy evaluation . Medical condition would unsafe use alphablocker . The use concomitant drug would confound efficacy evaluation . The use concomitant drug would unsafe alphablocker .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Benign prostatic hyperplasia , BPH , alpha blocker</keyword>
</DOC>